Suven gets US FDA nod for Hyderabad plant

New Delhi, June 11 (UNI) Suven Life Sciences Ltd today said its Hyderabad facility has got the US FDA's approval for manufacture and supply of active pharmaceutical ingredients (APIs) under current Good Manufacturing Practice (cGMP) standards.

The company has filed eight Drug Master Files (DMF) from this facility which is now FDA complaint under cGMP. With partner ANDA approvals, it can supply the APIs in future thus generating new revenues in due course of time.

Hyderabad-based Suven Life Sciences, a Collaborative Research Partner (CRP) in drug discovery, is in contract research and manufacturing services (CRAMS) since 1995 and Drug Discovery and Development Support Services (DDDSS) since 2005.

It is engaged in discovering new chemical entities in Central Nervous System (CNS) therapeutic areas like alzheimer's, cognitive impairment, dementia, depression, parkinson's disease and obesity which are at various phases of preclinical development.

It has an R&D strength of more than 190 professionals with a state-of-the-art infrastructure for drug discovery and development activities with 40 clinical research professionals and the front end project management services from New Jersey, the US.

UNI